Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
+$0.02 today
- Market cap
- $1.34B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
Volume 9.96M
Average 6.11M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Intellia Therapeutics, Inc.
NASDAQ:NTLA
Intrinsic Alpha fair value
Locked
Current Price
$9.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +9.1% | +92.2% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +9.1% over three years. Forward estimates point to Revenue at +92.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
CRISPR Therapeutics AG NASDAQ:CRSP | $4.10B | $42.24 | Not rated | -9.2 | -21.02% |
Beam Therapeutics Inc. NASDAQ:BEAM | $2.36B | $22.83 | Not rated | -52.3 | +1.65% |
uniQure N.V. NASDAQ:QURE | $1.67B | $23.81 | Not rated | -14.1 | -27.49% |
Precigen, Inc. NASDAQ:PGEN | $1.63B | $4.54 | Not rated | -7.1 | +6.67% |
MeiraGTx Holdings plc NASDAQ:MGTX | $881.67M | $9.18 | Not rated | -7.4 | +9.56% |
Sana Biotechnology, Inc. NASDAQ:SANA | $605.26M | $2.02 | Not rated | -3.5 | -46.13% |
Editas Medicine, Inc. NASDAQ:EDIT | $334.92M | $2.17 | Not rated | -2.4 | -30.77% |
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | $252.48M | $2.30 | Not rated | -1.7 | -25.70% |
Caribou Biosciences, Inc. NASDAQ:CRBU | $39.10M | $0.36 | Not rated | -1.1 | -72.03% |
Continue the stock analysis
Jump to another research area for this company.